IL96666A - Pharmaceutical preparations containing polytocyclic compounds - Google Patents

Pharmaceutical preparations containing polytocyclic compounds

Info

Publication number: IL96666A
Authority: IL; Israel
Prior art keywords: composition; bis; compounds; hiv; tetraazacyclotetradecane
Prior art date: 1989-12-21

Application number

IL9666690A

Other languages

English (en)

Hebrew (he)

Other versions

IL96666A0 (en

Original Assignee

Johnson Matthey Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-12-21

Filing date

1990-12-14

Publication date

1996-01-31

1990-12-14 Application filed by Johnson Matthey Plc filed Critical Johnson Matthey Plc

1991-09-16 Publication of IL96666A0 publication Critical patent/IL96666A0/xx

1996-01-31 Publication of IL96666A publication Critical patent/IL96666A/en

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
125000002950 monocyclic group Chemical group 0.000 title claims description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 6
150000001923 cyclic compounds Chemical class 0.000 claims abstract description 3
229910052757 nitrogen Inorganic materials 0.000 claims abstract description 3
150000001875 compounds Chemical class 0.000 claims description 46
239000000203 mixture Substances 0.000 claims description 14
125000002947 alkylene group Chemical group 0.000 claims description 8
125000003118 aryl group Chemical group 0.000 claims description 8
-1 polyoxoethylene Polymers 0.000 claims description 8
239000003085 diluting agent Substances 0.000 claims description 6
239000000546 pharmaceutical excipient Substances 0.000 claims description 5
231100000252 nontoxic Toxicity 0.000 claims description 4
230000003000 nontoxic effect Effects 0.000 claims description 4
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
150000007942 carboxylates Chemical class 0.000 claims description 3
150000002148 esters Chemical class 0.000 claims description 3
229940002612 prodrug Drugs 0.000 claims description 3
239000000651 prodrug Substances 0.000 claims description 3
239000002253 acid Substances 0.000 claims description 2
125000003368 amide group Chemical group 0.000 claims description 2
150000004696 coordination complex Chemical group 0.000 claims description 2
125000004122 cyclic group Chemical group 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
239000002552 dosage form Substances 0.000 claims 1
125000005647 linker group Chemical group 0.000 claims 1
238000011282 treatment Methods 0.000 abstract description 15
208000036142 Viral infection Diseases 0.000 abstract description 3
125000004429 atom Chemical group 0.000 abstract description 3
230000009385 viral infection Effects 0.000 abstract description 3
206010038997 Retroviral infections Diseases 0.000 abstract description 2
239000004480 active ingredient Substances 0.000 abstract description 2
125000003277 amino group Chemical group 0.000 abstract 1
101001110286 Homo sapiens Ras-related C3 botulinum toxin substrate 1 Proteins 0.000 description 15
102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 15
208000031886 HIV Infections Diseases 0.000 description 11
241000713772 Human immunodeficiency virus 1 Species 0.000 description 11
241000713340 Human immunodeficiency virus 2 Species 0.000 description 11
238000000034 method Methods 0.000 description 10
210000004027 cell Anatomy 0.000 description 5
238000012360 testing method Methods 0.000 description 5
241000725303 Human immunodeficiency virus Species 0.000 description 4
241000700605 Viruses Species 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
230000000694 effects Effects 0.000 description 4
208000030507 AIDS Diseases 0.000 description 3
125000002619 bicyclic group Chemical group 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
125000004433 nitrogen atom Chemical group N* 0.000 description 3
UEUPDYPUTTUXLJ-UHFFFAOYSA-N 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane;octahydrochloride Chemical compound Cl.Cl.Cl.Cl.Cl.Cl.Cl.Cl.C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 UEUPDYPUTTUXLJ-UHFFFAOYSA-N 0.000 description 2
241000282414 Homo sapiens Species 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
239000003814 drug Substances 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
BGHCVCJVXZWKCC-UHFFFAOYSA-N tetradecane Chemical compound CCCCCCCCCCCCCC BGHCVCJVXZWKCC-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
MDAXKAUIABOHTD-UHFFFAOYSA-N 1,4,8,11-tetraazacyclotetradecane Chemical compound C1CNCCNCCCNCCNC1 MDAXKAUIABOHTD-UHFFFAOYSA-N 0.000 description 1
SCMFKRCYKTYWIW-UHFFFAOYSA-N 1-[3-(1,4,8,11-tetrazacyclotetradec-1-yl)propyl]-1,4,8,11-tetrazacyclotetradecane Chemical compound C1CCNCCNCCCNCCN1CCCN1CCCNCCNCCCNCC1 SCMFKRCYKTYWIW-UHFFFAOYSA-N 0.000 description 1
QWTAISGGJUDPMS-UHFFFAOYSA-N 1-[5-(1,4,8,11-tetrazacyclotetradec-2-yl)pentyl]-1,4,8,11-tetrazacyclotetradecane Chemical compound C1CCNCCNCCCNCCN1CCCCCC1CNCCCNCCNCCCN1 QWTAISGGJUDPMS-UHFFFAOYSA-N 0.000 description 1
KQMSYFWGOQIZPD-UHFFFAOYSA-N 6-(1,4,8,11-tetrazacyclotetradec-6-yl)-1,4,8,11-tetrazacyclotetradecane Chemical compound C1NCCNCCCNCCNCC1C1CNCCNCCCNCCNC1 KQMSYFWGOQIZPD-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
206010001513 AIDS related complex Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000736839 Chara Species 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000005074 Retroviridae Infections Diseases 0.000 description 1
239000005864 Sulphur Substances 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229910017052 cobalt Inorganic materials 0.000 description 1
239000010941 cobalt Substances 0.000 description 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
229940124558 contraceptive agent Drugs 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
KATXJJSCAPBIOB-UHFFFAOYSA-N cyclotetradecane Chemical compound C1CCCCCCCCCCCCC1 KATXJJSCAPBIOB-UHFFFAOYSA-N 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
239000000539 dimer Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000009510 drug design Methods 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
231100000086 high toxicity Toxicity 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000002262 irrigation Effects 0.000 description 1
238000003973 irrigation Methods 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
150000002678 macrocyclic compounds Chemical class 0.000 description 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
150000002815 nickel Chemical class 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
229910052703 rhodium Inorganic materials 0.000 description 1
239000010948 rhodium Substances 0.000 description 1
MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Virology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

IL9666690A 1989-12-21 1990-12-14 Pharmaceutical preparations containing polytocyclic compounds IL96666A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/454,418 US5021409A (en)	1989-12-21	1989-12-21	Antiviral cyclic polyamines

Publications (2)

Publication Number	Publication Date
IL96666A0 IL96666A0 (en)	1991-09-16
IL96666A true IL96666A (en)	1996-01-31

Family

ID=23804523

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9666690A IL96666A (en)	1989-12-21	1990-12-14	Pharmaceutical preparations containing polytocyclic compounds

Country Status (17)

Country	Link
US (1)	US5021409A (de)
EP (1)	EP0434385B1 (de)
JP (1)	JP3133345B2 (de)
KR (1)	KR0180019B1 (de)
AT (1)	ATE130514T1 (de)
AU (1)	AU639514B2 (de)
CA (1)	CA2032261C (de)
DE (1)	DE69023748T2 (de)
DK (1)	DK0434385T3 (de)
ES (1)	ES2079453T3 (de)
GR (1)	GR3018206T3 (de)
HU (2)	HUT67031A (de)
IE (1)	IE71640B1 (de)
IL (1)	IL96666A (de)
NZ (1)	NZ236463A (de)
PT (1)	PT96289B (de)
ZA (1)	ZA9010184B (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9105489D0 (en) *	1991-03-15	1991-05-01	Johnson Matthey Plc	Improvements in chemical compounds
GB9126677D0 (en) *	1991-12-16	1992-02-12	Johnson Matthey Plc	Improvements in chemical compounds
GB9400411D0 (en) *	1994-01-11	1994-03-09	Johnson Matthey Plc	Improvements in chemical compounds
KR100447303B1 (ko) *	1994-01-11	2005-08-23	아노메드 인코포레이티드	고리형폴리아민
US5663161A (en) *	1995-02-17	1997-09-02	The Research Foundation Of State University Of New York	Anti-viral triaza compounds
US5612478A (en) *	1995-03-30	1997-03-18	Johnson Matthey Plc	Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) *	1995-05-02	1997-02-25	Johnson Matthey Plc	Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US6506770B1 (en) *	1996-06-06	2003-01-14	Anormed, Inc.	Antiviral compounds
GB9511357D0 (en) *	1995-06-06	1995-08-02	Johnson Matthey Plc	Improved antiviral compounds
US6261763B1 (en) *	1995-06-07	2001-07-17	Progenics Pharmaceuticals, Inc.	Fluorescence resonance energy transfer screening assay for the identification of compounds that are capable of abrogating macrophage-tropic HIV-1 cell fusion
WO1997001360A2 (en) *	1995-06-26	1997-01-16	Concat, Ltd.	Compounds with chelation affinity and selectivity for first transition series elements and their use in medical therapy and diagnosis
US5608061A (en) *	1995-08-02	1997-03-04	Johnson Matthey Plc	Process for preparing 1,4,8,11-tetraazacyclotetradecane
US7118859B2 (en)	1996-01-17	2006-10-10	Progenics Pharmaceuticals, Inc.	Methods for inhibiting HIV-1 infection
US7858298B1 (en)	1996-04-01	2010-12-28	Progenics Pharmaceuticals Inc.	Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
US6344545B1 (en)	1996-06-14	2002-02-05	Progenics Pharmaceuticals, Inc.	Method for preventing HIV-1 infection of CD4+ cells
US20040086528A1 (en) *	1996-06-14	2004-05-06	Progenics Pharmaceuticals, Inc.	Uses of a chemokine receptor for inhibiting HIV-1 infection
AU5241099A (en) *	1998-07-31	2000-02-21	Trustees Of Columbia University In The City Of New York, The	Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
US20080015348A1 (en) *	1998-12-16	2008-01-17	Progenics Pharmaceuticals, Inc.	Nucleic acids encoding polypeptides of anti-CCR5 antibodies
US20040228869A1 (en) *	1998-12-16	2004-11-18	Progenics Pharmaceuticals, Inc.	Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
US6365583B1 (en)	1999-02-02	2002-04-02	Anormed, Inc.	Methods to enhance white blood cell count
US6750348B1 (en)	1999-03-24	2004-06-15	Anormed, Inc.	Chemokine receptor binding heterocyclic compounds
AP1654A (en)	1999-03-24	2006-09-01	Anormed Inc	Chemokine receptor binding heterocyclic compounds.
US6649587B1 (en)	1999-04-30	2003-11-18	Slil Biomedical Corporation	Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
US6482943B1 (en)	1999-04-30	2002-11-19	Slil Biomedical Corporation	Quinones as disease therapies
US7312244B2 (en) *	1999-04-30	2007-12-25	Cellgate, Inc.	Polyamine analog-amino acid conjugates useful as anticancer agents
IL146127A0 (en)	1999-04-30	2002-07-25	Slil Biomedical Corp	Conformationally restricted polymine analogs as disease therapies
WO2000066175A2 (en) *	1999-04-30	2000-11-09	Slil Biomedical Corporation	Conjugates as therapies for cancer and prostate diseases
US8271316B2 (en) *	1999-12-17	2012-09-18	Buzzmetrics Ltd	Consumer to business data capturing system
WO2001044229A1 (en) *	1999-12-17	2001-06-21	Anormed Inc.	Chemokine receptor binding heterocyclic compounds
US20030072715A1 (en) *	2000-08-02	2003-04-17	Benjamin Frydman	Cyclic polyamine compounds for cancer therapy
US6864265B2 (en) *	2000-09-15	2005-03-08	Anormed, Inc.	Chemokine receptor binding heterocyclic compounds
US7138119B2 (en) *	2000-09-15	2006-11-21	Progenics Pharmaceuticals, Inc.	Compositions and methods for inhibition of HIV-1 infection
DK1317451T3 (da)	2000-09-15	2006-12-18	Anormed Inc	Kemokinreceptorbindende heterocykliske forbindelser
MXPA03002772A (es)	2000-09-29	2003-07-28	Anormed Inc	Procedimiento para la preparacion de poliaminas ciclicas que contienen nitrogeno en el anillo n-1 protegidos y productos de los mismos.
US7060273B2 (en) *	2001-04-06	2006-06-13	Progenics Pharmaceuticals, Inc.	Methods for inhibiting HIV-1 infection
US7169750B2 (en) *	2001-07-31	2007-01-30	Anormed, Inc.	Methods to mobilize progenitor/stem cells
JP5137288B2 (ja) *	2001-07-31	2013-02-06	アノーメッドインコーポレイティド	前駆／幹細胞を動員する方法
US6982351B2 (en) *	2001-12-07	2006-01-03	Cellgate, Inc.	Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor
US7354932B2 (en) *	2001-12-21	2008-04-08	Anormed, Inc.	Chemokine receptor binding heterocyclic compounds with enhanced efficacy
CN1596255A (zh)	2001-12-21	2005-03-16	阿诺麦德股份有限公司	具有强效的与趋化因子受体结合的杂环化合物
US7122185B2 (en) *	2002-02-22	2006-10-17	Progenics Pharmaceuticals, Inc.	Anti-CCR5 antibody
CA2520259A1 (en)	2003-04-11	2004-10-28	Anormed Inc.	Cxcr4 chemokine receptor binding compounds
CA2517077C (en) *	2003-04-22	2013-03-12	Anormed Inc.	Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7501518B2 (en) *	2003-04-22	2009-03-10	Genzyme Corporation	Methods of making 2,6-diaryl piperidine derivatives
WO2005059107A2 (en) *	2003-12-11	2005-06-30	Anormed Inc.	Chemokine receptor binding compounds
US7498346B2 (en) *	2003-12-11	2009-03-03	Genzyme Corporation	Chemokine receptor binding compounds
EP1796716A4 (de) *	2004-08-13	2010-09-08	Anormed Inc	Chemokin-kombinationen zur mobilisierung von vorläufer/stammzellen
WO2006138350A2 (en) *	2005-06-15	2006-12-28	Anormed Inc.	Chemokine receptor binding compounds
EP1924265A4 (de) *	2005-08-16	2010-06-02	Genzyme Corp	Chemokinrezeptor-bindende verbindungen
CA2619828A1 (en)	2005-08-19	2007-02-22	Genzyme Corporation	Methods to enhance chemotherapy
AU2006340074A1 (en) *	2006-02-24	2007-09-20	Genzyme Corporation	Methods for increasing blood flow and/or promoting tissue regeneration
AU2007281090A1 (en) *	2006-08-02	2008-02-07	Genzyme Corporation	Combination therapy
MX2009001445A (es) *	2006-08-07	2009-02-18	Genzyme Corp	Terapia de combinacion.
US20150030561A1 (en)	2011-05-16	2015-01-29	Genzyme Corp.	Use of CXCR4 Antagonists
CA3026154A1 (en)	2015-06-03	2016-12-08	The University Of Queensland	Mobilizing agents and uses therefor
WO2017106332A1 (en)	2015-12-14	2017-06-22	X4 Pharmaceuticals, Inc.	Methods for treating cancer
ES2907489T3 (es)	2015-12-14	2022-04-25	X4 Pharmaceuticals Inc	Métodos para el tratamiento del cáncer
WO2017106630A1 (en)	2015-12-18	2017-06-22	The General Hospital Corporation	Polyacetal polymers, conjugates, particles and uses thereof
HUE060517T2 (hu)	2015-12-22	2023-03-28	X4 Pharmaceuticals Inc	Immunhiányos betegség kezelésére szolgáló eljárások
WO2017177230A1 (en)	2016-04-08	2017-10-12	X4 Pharmaceuticals, Inc.	Methods for treating cancer
WO2017223229A1 (en)	2016-06-21	2017-12-28	X4 Pharmaceuticals, Inc.	Cxcr4 inhibitors and uses thereof
JP7054529B2 (ja)	2016-06-21	2022-04-14	エックス４ファーマシューティカルズ，インコーポレイテッド	Ｃｘｃｒ４阻害剤およびその使用
CA3027500A1 (en)	2016-06-21	2017-12-28	X4 Pharmaceuticals, Inc.	Cxcr4 inhibitors and uses thereof
WO2018106738A1 (en)	2016-12-05	2018-06-14	Massachusetts Institute Of Technology	Brush-arm star polymers, conjugates and particles, and uses thereof
JP7412341B2 (ja)	2017-10-31	2024-01-12	エディジーンバイオテクノロジーインコーポレイテッド	造血幹細胞および前駆細胞の増幅のための組成物および方法
US20190343885A1 (en)	2017-10-31	2019-11-14	Magenta Therapeutics Inc.	Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
US11260079B2 (en)	2017-12-06	2022-03-01	Magenta Therapeutics, Inc.	Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
CN111712262A (zh)	2017-12-06	2020-09-25	美真达治疗公司	用于动员造血干细胞和祖细胞的给药方案
AU2019205262A1 (en)	2018-01-03	2020-07-23	Magenta Therapeutics Inc.	Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
US10548889B1 (en)	2018-08-31	2020-02-04	X4 Pharmaceuticals, Inc.	Compositions of CXCR4 inhibitors and methods of preparation and use
WO2020112195A1 (en)	2018-11-30	2020-06-04	Yale University	Compositions, technologies and methods of using plerixafor to enhance gene editing
WO2021087406A1 (en)	2019-11-01	2021-05-06	Magenta Therapeutics, Inc.	Dosing regimens for the mobilization of hematopoietic stem and progentor cells
JP2023517956A (ja)	2020-03-10	2023-04-27	エックス４ファーマシューティカルズ，インコーポレイテッド	好中球減少症を処置する方法
MX2022013493A (es)	2020-04-27	2023-02-22	Magenta Therapeutics Inc	Metodos y composiciones para transducir celulas madre y progenitoras hematopoyeticas in vivo.
EP4308694A1 (de)	2021-03-16	2024-01-24	Magenta Therapeutics, Inc.	Dosierschemata zur mobilisierung hämatopoetischer stammzellen für stammzelltransplantationen bei patienten mit multiplem myelom
WO2025224720A1 (en)	2024-04-24	2025-10-30	Biolinerx Ltd.	Methods of selecting treatment regimen against solid tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4156683A (en) *	1973-03-26	1979-05-29	Schering Corporation	Complexes of macrocyclic compounds
FR2614020B1 (fr) *	1987-04-14	1989-07-28	Guerbet Sa	Nouveaux ligands cycliques azotes, complexes metalliques formes par ces ligands, compositions de diagnostic contenant ces complexes et procede de preparation des ligands.
DE3713842A1 (de) *	1987-04-22	1988-11-17	Schering Ag	Substituierte cyclische komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
DE4035760A1 (de) *	1990-11-08	1992-05-14	Schering Ag	Mono-n-substituierte 1,4,7,10-tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel

1989
- 1989-12-21 US US07/454,418 patent/US5021409A/en not_active Expired - Lifetime
1990
- 1990-12-14 IL IL9666690A patent/IL96666A/en not_active IP Right Cessation
- 1990-12-14 NZ NZ236463A patent/NZ236463A/en unknown
- 1990-12-14 CA CA002032261A patent/CA2032261C/en not_active Expired - Lifetime
- 1990-12-14 AU AU68090/90A patent/AU639514B2/en not_active Ceased
- 1990-12-18 ZA ZA9010184A patent/ZA9010184B/xx unknown
- 1990-12-19 ES ES90313899T patent/ES2079453T3/es not_active Expired - Lifetime
- 1990-12-19 DE DE69023748T patent/DE69023748T2/de not_active Expired - Lifetime
- 1990-12-19 DK DK90313899.8T patent/DK0434385T3/da active
- 1990-12-19 AT AT90313899T patent/ATE130514T1/de not_active IP Right Cessation
- 1990-12-19 KR KR1019900021096A patent/KR0180019B1/ko not_active Expired - Fee Related
- 1990-12-19 EP EP90313899A patent/EP0434385B1/de not_active Expired - Lifetime
- 1990-12-20 IE IE461990A patent/IE71640B1/en not_active IP Right Cessation
- 1990-12-20 PT PT96289A patent/PT96289B/pt not_active IP Right Cessation
- 1990-12-20 HU HU908367A patent/HUT67031A/hu unknown
- 1990-12-21 JP JP02404955A patent/JP3133345B2/ja not_active Expired - Lifetime
1994
- 1994-07-11 HU HU94P/P00011P patent/HU210534A9/hu unknown
1995
- 1995-11-23 GR GR950403260T patent/GR3018206T3/el unknown

Also Published As

Publication number	Publication date
KR0180019B1 (ko)	1999-03-20
PT96289A (pt)	1991-10-15
EP0434385A2 (de)	1991-06-26
DE69023748T2 (de)	1996-05-02
JPH06219945A (ja)	1994-08-09
GR3018206T3 (en)	1996-02-29
IE71640B1 (en)	1997-02-26
CA2032261C (en)	2002-04-23
ATE130514T1 (de)	1995-12-15
KR910011267A (ko)	1991-08-07
AU6809090A (en)	1991-06-27
EP0434385A3 (en)	1992-03-04
DE69023748D1 (de)	1996-01-04
ES2079453T3 (es)	1996-01-16
CA2032261A1 (en)	1991-06-22
AU639514B2 (en)	1993-07-29
JP3133345B2 (ja)	2001-02-05
EP0434385B1 (de)	1995-11-22
DK0434385T3 (da)	1995-12-18
IL96666A0 (en)	1991-09-16
US5021409A (en)	1991-06-04
ZA9010184B (en)	1991-11-27
HUT67031A (en)	1995-01-30
PT96289B (pt)	1998-06-30
HU210534A9 (en)	1995-04-28
NZ236463A (en)	1992-04-28
HU908367D0 (en)	1991-07-29
IE904619A1 (en)	1991-07-17

Legal Events

Date	Code	Title
1996-07-23	FF	Patent granted
1997-03-18	KB	Patent renewed
2001-04-30	KB	Patent renewed
2004-02-08	HP	Change in proprietorship
2004-02-19	HP	Change in proprietorship
2005-02-20	KB	Patent renewed
2009-06-15	KB	Patent renewed
2011-07-31	EXP	Patent expired

Publication	Publication Date	Title
CA2032261C (en)	2002-04-23	Antiviral polyheterocyclic dimers
US6001826A (en)	1999-12-14	Chemical compounds
US5736527A (en)	1998-04-07	Method of treating HIV in humans by administration of ddI and hydroxycarbamide
Hammer et al.	1987	Synergistic activity of granulocyte-macrophage colony-stimulating factor and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro
US4985465A (en)	1991-01-15	Method for inhibiting viral and retroviral infections
JPH0232093A (ja)	1990-02-01	抗レトロウィルスジフルオロ化ヌクレオシド類
WO1992016494A1 (en)	1992-10-01	Long chain antiviral compounds
ES2148234T3 (es)	2000-10-16	Composicion farmaceutica a base de flavopereirina y su utilizacion en el tratamiento del virus vih.
EA015132B1 (ru)	2011-06-30	Лекарственное средство для лечения вирусных инфекций
EP0392666B1 (de)	1994-07-20	Anti-HIV Zusammensetzungen
WO2006104292A1 (en)	2006-10-05	Pharmaceutical composition comprising arsenic acid, meta-arsenite, and pharmaceutically acceptable salts
US5026732A (en)	1991-06-25	Use of avarone for the control of AIDS and ARC
KR100532542B1 (ko)	2005-12-01	아르세닉산, 메타아르세나이트 또는 이들의 약제학적허용가능한 염을 함유한 에이즈 예방 및 치료용 약제 조성물
PT97609A (pt)	1992-02-28	Processo para a preparacao de uma composicao farmaceutica para o tratamento de celulas infectadas com o virus da imunodeficiencia humana e dispositivo ou artigo tratado com essa composicao
JPH05117143A (ja)	1993-05-14	抗ウイルス剤
AU718325B2 (en)	2000-04-13	Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread
JPH01168616A (ja)	1989-07-04	糖ラクタムを含有する抗ウイルス剤
WO1995017875A2 (en)	1995-07-06	MIXTURES OF DIDEOXYNUCLEOSIDES AND D-ASPARTIC ACID β-HYDROXAMATE FOR INHIBITING RETROVIRAL SPREAD
JPH01172321A (ja)	1989-07-07	６−０−置換−Ｄ−グルコ−δ−ラクタムを含有する抗ウイルス剤
JPH05105626A (ja)	1993-04-27	抗ウイルス剤
JPWO1995020388A1 (ja)	1996-06-25	抗ｈｉｖ剤
KR19990072051A (ko)	1999-09-27	티아민디술피드류및이를유효성분으로하는의약